Armata Pharmaceuticals, Inc. 8-K

Summary

FDA Breakthrough Therapy designation for AP-SA02. The designation covers adjunct treatment of complicated bloodstream infections caused by methicillin-sensitive or methicillin-resistant Staphylococcus aureus and is intended to expedite development and review. It follows Phase 1b/2a data showing higher and earlier clinical cure rates with AP-SA02 plus antibiotics than with antibiotics alone; the candidate also has Fast Track and Qualified Infectious Disease Product designations.

Key Figures

• Phase 1b/2a study: 100% of AP-SA02-treated patients maintained clinical response without relapse at the assessment 28 days after completing best available antibiotic therapy, vs 75% with placebo plus therapy.
• AP-SA02 was administered intravenously every six hours for five days; the regimen was well tolerated, with no serious adverse events attributed to AP-SA02.
• A $28.7M Department of War award partially supports the study, End-of-Phase 2 activities, and preparation for Phase 3.

Investor Takeaways

• Armata anticipates starting a Phase 3 superiority study in complicated S. aureus bloodstream infections in H2 2026; Phase 3 results will test whether the Phase 2 findings are confirmed.